TEVA:
Analysis & Opinions
-
July 02, 2010
If biotech companies are buying each other, should investors get in on the action?
-
June 30, 2010
When the market slows down, small cap stocks are the answer. Here are three proven small cap picks that may just get ...
-
April 21, 2010
Eli Lilly will have more than $5 billion in annual free cash flow over the next few years to try and stem its ...
-
April 09, 2010
The Middle East offers opportunity for long-term investors in Egypt, Israel and Turkey.
-
January 27, 2010
Any healthcare reform will include severe cost cutting. Giving your portfolio a dose of generic-dug makers will help ...
-
October 15, 2009
A couple of key investment merits should eventually allow J&J’s share price to increase markedly.
-
August 25, 2009
Merck regaining its swagger, after a steady decline last year.
-
July 15, 2009
Investors are waiting for J&J to return to its heyday of double-digit growth.
-
April 15, 2009
President Obama reminds investors of the importance of emerging markets.
-
March 09, 2009
If you're losing sleep over the down economy, these pharmaceutical picks might help you sleep a little easier.
-
January 23, 2009
This pharma faces patent expirations on its two key drugs, but its valuation reflects these risks and the firm has ...
-
October 03, 2008
Security and stability reign at Abbott Labs. The drug maker has avoided major recalls and has rock solid patent ...
-
May 15, 2008
Success in generic drugs is all about high volume, low prices and global presence. Israel's Teva Pharmaceuticals ...
-
March 04, 2008
Troubled drugmaker Biovail could be in play as Eugene Melnyk said he'll either sell his 11% stake or take the ...
-
September 26, 2007
Billions of dollars in brand name drugs are set to lose patent protection, and Barr pharmaceuticals is ready to take ...
-
April 19, 2007
A look at the possible growing pains for the generic-drug manufacturing giant after it acquired Crotian drug ...
-
March 14, 2007
Generic drug manufacturers continue pose a potent threat to the established "big pharma" companies.
-
January 24, 2007
While Pfizer's current issues are cause for concern, the company's long-term plans make it worth a second look.
-
April 13, 2006
A look at the recent quarter of one of the leading biotech companies.
